Efficacy and Tolerability of Tasipimidine in Sleepless Patients
- First Posted Date
- 2025-05-04
- Last Posted Date
- 2025-05-04
- Lead Sponsor
- Orion Corporation, Orion Pharma
- Target Recruit Count
- 153
- Registration Number
- NCT06956495
- Locations
- 🇫🇮
Terveystalo Helsinki Uniklinikka, Helsinki, Finland
Two-part, First-in-Human Study on ODM-212 in Subjects with Selected Advanced Solid Tumours
- First Posted Date
- 2024-12-10
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Orion Corporation, Orion Pharma
- Target Recruit Count
- 315
- Registration Number
- NCT06725758
- Locations
- 🇬🇧
Royal Marsden Hospital, London, UK, London, United Kingdom
Efficacy and Safety of Remo-Wax® Oil (RWO) in Subjects With Isolated Itching of the External Ear Canal
Not Applicable
Completed
- Conditions
- Itching
- Interventions
- Device: Remo-Wax® Oil
- First Posted Date
- 2023-04-13
- Last Posted Date
- 2023-10-06
- Lead Sponsor
- Orion Corporation, Orion Pharma
- Target Recruit Count
- 36
- Registration Number
- NCT05811039
- Locations
- 🇱🇹
Vilnius University Hospital, Vilnius, Lithuania
Study to Compare Relative Bioavailability of 3 Indacaterol/Glycopyrronium Test Products and Reference Product
Phase 1
Completed
- Conditions
- Healthy Volunteers
- Interventions
- Drug: Indacaterol/glycopyrronium
- First Posted Date
- 2022-03-18
- Last Posted Date
- 2022-07-13
- Lead Sponsor
- Orion Corporation, Orion Pharma
- Target Recruit Count
- 24
- Registration Number
- NCT05288075
- Locations
- 🇫🇮
CRST Helsinki Oy, Helsinki, Finland
Comparison of Tiotropium Absorption From Tiotropium Easyhaler and Spiriva HandiHaler
- First Posted Date
- 2022-02-18
- Last Posted Date
- 2022-08-18
- Lead Sponsor
- Orion Corporation, Orion Pharma
- Target Recruit Count
- 88
- Registration Number
- NCT05246046
- Locations
- 🇫🇮
Clinical Pharmacology Unit, Orion Corporation, Espoo, Finland
Use of Buventol Easyhaler and Bufomix Easyhaler in Methacoline Challenge Testing
Phase 4
Completed
- Conditions
- Asthma
- Interventions
- Drug: Ventoline® Evohaler® 100 µg/inhalation pMDIDrug: Buventol® Easyhaler® 200 µg/inhalation dmDPIDrug: Bufomix® Easyhaler® 160/4.5 µg/inhalation dmDPI
- First Posted Date
- 2021-10-19
- Last Posted Date
- 2023-09-05
- Lead Sponsor
- Orion Corporation, Orion Pharma
- Target Recruit Count
- 180
- Registration Number
- NCT05084222
- Locations
- 🇫🇮
Helsinki University Hospital, Helsinki, Finland
🇫🇮Tampere University Hospital, Tampere, Finland
Effect of Electronic Monitoring and Feedback on Adherence to Easyhaler Controller Medication in Patients With Asthma
Phase 4
Completed
- Conditions
- Asthma
- Interventions
- Other: Reminders and feedback to improve adherenceOther: No reminders and feedback to improve adherence
- First Posted Date
- 2021-05-03
- Last Posted Date
- 2024-11-04
- Lead Sponsor
- Orion Corporation, Orion Pharma
- Target Recruit Count
- 158
- Registration Number
- NCT04869384
- Locations
- 🇩🇪
MECS Research GmbH, Berlin, Germany
Absorption of Indacaterol and Glycopyrronium From Ultibro Breezhaler
Phase 1
Completed
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2021-04-22
- Last Posted Date
- 2021-09-28
- Lead Sponsor
- Orion Corporation, Orion Pharma
- Target Recruit Count
- 34
- Registration Number
- NCT04856098
- Locations
- 🇫🇮
CRST Helsinki Oy, Helsinki, Finland
Pharmacokinetic Study Comparing Tiotropium Easyhaler® and Spiriva® HandiHaler®
Phase 1
Completed
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2021-04-20
- Last Posted Date
- 2021-10-25
- Lead Sponsor
- Orion Corporation, Orion Pharma
- Target Recruit Count
- 43
- Registration Number
- NCT04850144
- Locations
- 🇫🇮
Clinical Pharmacology Unit, Orion Corporation, Espoo, Finland
Switch of Budesonide-formoterol Dry Powder Inhalers at Pharmacy in Norway
Terminated
- Conditions
- AsthmaCOPD
- First Posted Date
- 2020-12-11
- Last Posted Date
- 2021-09-23
- Lead Sponsor
- Orion Corporation, Orion Pharma
- Target Recruit Count
- 29
- Registration Number
- NCT04663386
- Locations
- 🇳🇴
Flattum Legesenter, Hønefoss, Norway
© Copyright 2025. All Rights Reserved by MedPath